Windlas Biotech Q4 FY26: Sales up 18%, PAT slips

Share price and the key numbers investors tracked

Windlas Biotech Ltd’s share price closed at ₹882.85, up ₹9.10 or 1.04% for the day. The latest quarterly update for the period ending March 2026 (Q4 FY26) shows revenue growth continuing, while profitability was slightly lower than the same quarter last year. Net sales for Q4 FY26 were reported at ₹238.50 crore. Net profit for the quarter was stated at ₹15.99 crore, a year-on-year decline of about 1.78% to 1.79% versus the corresponding quarter.

The data also indicates sequential improvement, with the company recording a 6.6% jump in quarterly net profit compared with the prior three-month period. That quarter-on-quarter increase matters because it contrasts with the year-on-year dip, suggesting that near-term earnings momentum improved versus Q3 FY26. Alongside results, the company declared a dividend and scheduled an investor conference call, both of which often influence short-term attention on the stock.

Q4 FY26 performance: higher sales, slightly lower profit

For the quarter ended March 2026, Windlas Biotech’s consolidated net sales rose 17.66% to ₹238.50 crore, compared with ₹202.71 crore in March 2025. Operating profit for March 2026 was listed at ₹25.24 crore. Other income was ₹4.40 crore and interest cost was ₹1.48 crore, as per the quarterly table provided.

On the bottom line, the source text reports quarterly net profit at ₹15.99 crore in March 2026, down 1.79% from ₹16.28 crore in March 2025. In the detailed quarterly table, profit after tax (PAT) is shown at ₹16.02 crore for March 2026 versus ₹16.29 crore for March 2025, indicating a small difference likely driven by rounding or reporting conventions in the dataset. EBITDA for March 2026 was stated at ₹29.64 crore, down 2.79% from ₹30.49 crore in March 2025. EPS for the quarter decreased to ₹7.58 from ₹7.77.

Quarterly trend: what changed through FY26

The quarterly table shows a steady rise in net sales through FY26 from ₹210.09 crore in June 2025 to ₹238.50 crore in March 2026. Total expenditure also increased during the year, reaching ₹213.26 crore in March 2026. This combination helps explain why operating profit did not rise in line with revenue.

Profit before tax (PBT) for March 2026 was ₹20.16 crore, compared with ₹20.83 crore in March 2025. Tax expense for March 2026 was ₹4.15 crore. The prior quarter (December 2025) shows PAT of ₹14.95 crore and adjusted EPS of ₹7.09, which aligns with the statement that net profit rose 6.6% sequentially into March 2026.

Quarterly result snapshot (₹ crore)

Dividend declared: amount, date, and yield

Windlas Biotech declared a dividend of ₹6.30 per share on 21 May 2026. Based on the data provided, this corresponds to a dividend yield of 1.37%. Dividend actions are typically watched closely because they reflect board decisions on capital allocation, especially in periods where earnings are stable but not expanding sharply.

The dataset does not specify the record date or payment date for the dividend. Investors generally verify those details in the company’s exchange filings and corporate announcements.

FY26 full-year figures mentioned in the dataset

Beyond the March 2026 quarter, the data includes multiple FY26 profitability references. One line states: “Windlas Biotech FY26 Net Profit Rises 9% to Rs 66 Cr” dated May 22, 2026. Another section lists profits of ₹66.46 crore for Mar 2026 (FY26), ₹60.99 crore for Mar 2025 (FY25), and ₹58.19 crore for Mar 2024 (FY24).

Separately, an FY26 performance note in the dataset cites revenue at ₹904 crore, up 19% year-on-year, EBITDA margin at about 13.4%, and FY26 PAT at ₹83 crore (9.2% margin). These figures are presented in the provided text but differ from the ₹66.46 crore profit figure also included, so readers should reconcile the numbers against the company’s audited annual results and the specific consolidation scope used.

Revenue mix: India contribution in ₹ crore

The dataset also provides an India revenue contribution series in billions of INR, which converts to ₹ crore as follows: ₹852 crore last year, compared with ₹722 crore the year before. Earlier points listed are ₹601 crore, ₹491 crore, and ₹442 crore for preceding years in the series. While the “International” line is shown, no explicit figures are provided for it in the text.

This India-heavy contribution pattern, as shown in the dataset, is relevant for investors tracking domestic demand conditions and pricing dynamics in the Indian pharma manufacturing ecosystem.

What’s next: conference call and results-season dates

Windlas Biotech announced a conference call scheduled for August 11, 2026, at 11:30 AM IST. The same dataset references the quarter ended June 30, 2026, and includes a “Quarterly Results Announcement Date: Aug 10, 2026,” indicating a near-term event window that markets typically watch for commentary on demand, margins, and capacity utilisation.

The Q1 FY27 results are described as expected in the July-August 2026 window, aligned with broader NSE and BSE results season timelines for the quarter ending June 2026.

Key dates and market references

Street estimates in the dataset: Q1 FY27 revenue and PAT ranges

The provided text includes a Q1 FY27 preview with an estimated revenue range of ₹234 to ₹269 crore and a PAT range of ₹15 to ₹19 crore. It also references a Q1 FY26 base of ₹215 crore revenue and ₹18 crore net profit used to build the trailing-growth framework. Another line cites Windlas Biotech CMP at ₹851, separate from the closing price of ₹882.85 stated elsewhere in the dataset.

The same preview includes a 12-month target range of ₹953 to ₹1,064 (labelled as a Uniresearch estimate). These estimates are part of the provided material and should be treated as projections rather than reported financials.

Market impact: what the numbers imply, without forecasting

The reported Q4 FY26 data shows a clear revenue expansion year-on-year, with net sales up 17.66%. At the same time, EBITDA and EPS both declined versus the year-ago quarter, indicating that margin pressures or cost increases offset the top-line growth. The sequential rise in PAT from ₹14.95 crore in December 2025 to ₹15.99 crore (or ₹16.02 crore as per the table) in March 2026 suggests near-term improvement compared with the immediately preceding quarter.

For investors, the immediate decision points in the dataset are the upcoming results announcement timeline around August 2026, the scheduled conference call on August 11, and how management commentary aligns with the FY26 metrics cited in the material. Dividend yield at 1.37% provides an additional data point on shareholder returns, but it does not change the fact that quarterly profitability was marginally lower year-on-year.

Conclusion

Windlas Biotech’s Q4 FY26 print combines strong year-on-year sales growth with a small decline in net profit and EPS versus the March 2025 quarter. The company has also declared a ₹6.30 dividend and scheduled an August 11, 2026 conference call, while the dataset flags an August 10, 2026 results announcement date. The next confirmed milestones are the results-season updates for the quarter ended June 30, 2026 and the company’s conference call, where investors typically look for clarity on margins, demand, and the near-term financial trajectory.